( click to enlarge )Valeant Pharmaceuticals Intl Inc (NYSE:VRX) gained 12.78% to $30 after analysts at Morgan Stanley upgraded their rating to overweight and raised its price target to $42 per share from $33. The stock cleared key resistance level, signify a breakout and bullish reversal that support further follow-through and an initial test of the declining 100-day exponential moving average around the $34 levels. Keep on watch list.
( click to enlarge )Onconova Therapeutics Inc (NASDAQ:ONTX) has the perfect set up to make a nice run here. The break out point would be at 3.92. Trajectories of momentum indicators are turning up again and A/D chart shows serious accumulation. If it breaks above the 3.92 level, it could reach an initial target of 4.50 and then a secondary target at 4.75. Keep it on your screen on Thursday.
( click to enlarge )SCYNEXIS Inc (NASDAQ:SCYX) traded higher on Wednesday gaining nearly 26% after Guggenheim initiated coverage on shares with a Buy rating and $15 price target. Stock finally broke out of the bottom base formation accompanied by heavy volume. Momentum indicators are flashing bullish signals, with MACD climbing and RSI rising. Look for a quick run to $3.02 then on to 3.50.
( click to enlarge )Auris Medical Holding AG (NASDAQ:EARS) hit my scanner today with some impressive volume and closed up 39%. I expect some follow through on Thursday. The MACD has a positive crossover and the RSI remains in buy mode.
( click to enlarge )VirnetX Holding Corporation (NYSEMKT:VHC) is displaying a screaming buy divergence on the upside. A strong short-covering rally should emerge sooner or later. Keep it on your watch list going forward.
( click to enlarge )Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) needs to take out the $2.75 resistance area in order to convince bullish buyers at these levels.
( click to enlarge )EZCORP Inc (NASDAQ:EZPW) Resistance Breakout. Go long on the break of Wednesday’s high at 10.21
( click to enlarge )Netflix, Inc. (NASDAQ:NFLX) Watch this trend line for a upside break at $97 for short-term direction.
If you want to contact me for advertising opportunities on blog or twitter, then get in touch via email
Disclaimer : This is not an investment advisory, and should not be used to make investment decisions. Information in AC Investor Blog is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The charts provided here are not meant for investment purposes and only serve as technical examples. Don't consider buying or selling any stock without conducting your own due diligence.
Thanks for visiting AC Investor Blog.
AC
